References
- JT Lonergan, C Behling, H Pfander, TI Hassanein, WC. Marthews, Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens, Clin Infect Dis 31 (2000) 162–166.
- W Lewis, MC. Dalacas, Mitochondrial toxicity of antiviral drugs, Nat Med i (1995) 417–422.
- GJ Moyle, D Datta, S Mandalia, J Morlese, D Asboe, BG. Gazzard, Hyperlactatemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors, AIDS 16 (2002) 1341–1349.
- Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001; 33: 193–17.
- M John, CB Moore, IR James, D Nolan, EJ Mckinnon, SA. Mallal, Chronic hyperlactatemia in HIV infected patients on antiretroviral therapy, AIDS 6 (2001) 717–723.
- IS Fortgang, PC Belitsos, RE Chaisson, RD. Moore, Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analogue antiretroviral therapy, Am J Gastroenterol 90 (1995) 1433–1436.
- Falco V, Rodriguez D, Ribera E, Martinez E, Miro JM, Domingo P, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002; 34: 838846.
- B Fouty, F Freman, R. Reves, Riboflavin to treat nucleoside analogue-induced lactic acidosis, Lancet 352 (1998) 291–292.